Ahmed Alanazi | أحمد العنزي· @alanazi002 · X·· 1 day agoScore70
Body · original
🚨 #ESMO26 | Krascendo 1 (Phase 3)
🥇 First head-to-head KRAS G12C inhibitor trial
🥇 First KRAS G12C inhibitor to improve OS in NSCLC
Divarasib vs sotorasib/adagrasib, pretreated KRAS G12C NSCLC (N=338)
✅ mOS 17.7 vs 12.0 mo (HR 0.56)
✅ mPFS 9.8 vs 5.7 mo (HR 0.58)
✅ ORR 58% vs 32%
@myESMO @OncoAlert
21 views · 0 likes · 0 reposts · 0 replies
Conference abstracts
Krascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer
https://esmocongress.esmo.orgSource: Ahmed Alanazi | أحمد العنزي · x.com